Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 11/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228701 | 0.84 | KMT2A (0.49) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL21695505 | 0.73 | LMNA (0.74) | LMNACREBBPKMT2A | |
| SCHEMBL21695465 | 0.71 | LMNA (0.71) | LMNATNFCREBBPALDH1A1MAPT | |
| SCHEMBL10824415 | 0.71 | LMNA (1.00) | LMNATNFKAT2BCREBBPMAPT | |
| SCHEMBL9533319 | 0.69 | HPRT1 (0.64) | — | |
| SCHEMBL2962862 | 0.69 | LMNA (0.50) | LMNATNFKAT2BCREBBPALDH1A1 | |
| SCHEMBL2962063 | 0.69 | LMNA (0.50) | LMNATNFKAT2BCREBBPALDH1A1 | |
| SCHEMBL2970107 | 0.69 | ALDH1A1 (0.53) | LMNATNFCREBBPALDH1A1MEN1 | |
| SCHEMBL25230986 | 0.69 | LMNA (0.44) | LMNATNFKAT2BALDH1A1 | |
| SCHEMBL25227928 | 0.68 | CYP1A2 (0.48) | LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | GFB (ABC), LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | GFB (ABC), LLC | 2023-06-22 | — | — | US | disclosed |
| EP-4114838-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | Goldfinch Bio, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | CNR1, GPR119, CNR2 | LMNA 4272/4885TNF 4754/4885KAT2B 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.